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Recent advances in our understanding of the pathophysiological mechanisms of atherosclerosis have
created the need for better non-invasive imaging of vascular phenotype. Ultrasound is widely available,
inexpensive, and well suited for high-throughput screening in populations that are at risk for athero-
sclerosis. Novel ultrasonic approaches for the diagnosis of vascular changes in atherosclerosis include
(1) assessment of plaque composition by evaluation of the backscattering properties of tissue, (2)
assessment of the changes in arterial wall biomechanics, (3) assessment of plaque neovascularization,
and (4) molecular imaging of vascular phenotype changes on a subcellular level. It is thought that such
new imaging methodologies will lead to earlier detection of atherosclerosis, and better assessment of
the risk for aggressive disease progression. Novel therapies for atherosclerosis will undoubtedly
become available within the next decades, and non-invasive imaging techniques will be needed for
cost-efficient application of existing and new drugs.
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1. Introduction
Despite advances in primary and secondary prevention,1 car-
diovascular diseases remain the number one killer in
western countries.2 In addition, the decreases in mortality
rates have been levelling off in recent years in young
adults,1 while the prevalence of obesity and the metabolic
syndrome are increasing.3,4 Thus, it is estimated that cur-
rently up to 40% of the adult population in the USA would
fall into an intermediate risk category with a 6–20% risk of
developing symptomatic coronary heart disease within the
ensuing 10 years.5 Therefore, methods for further risk stra-
tification of individuals at intermediate risk are needed to
make more efficient use of the existing and future preven-
tion therapies.
Non-invasive imaging has developed rapidly in the last
years, and for all major imaging techniques (computed tom-
ography, single photon emission computed tomography, posi-
tron emission tomography, magnetic resonance, ultrasound)
recent advances have been used to better evaluate cardio-
vascular disease. For the assessment of atherosclerotic
disease, these methods have been used to look at plaque
morphology and composition, biomechanical properties of
vessels, or the consequences of plaque development on
blood flow or blood flow reserve. The ultimate goals of all
these efforts are three-fold: (1) earlier detection of patho-
physiological changes known to be involved in the develop-
ment of atherosclerosis; (2) better estimation of the risk
of rapid disease progression; and (3) gauge the risk for
complications in established atherosclerosis. Given the
fact that atherosclerosis is a complex, chronic disorder
involving inflammatory and proliferative signalling path-
ways, it is generally thought that imaging of molecular
events during all stages of the pathogenesis of atherosclero-
sis could contribute to better and earlier diagnostic assess-
ment, risk estimation, and measurement of treatment
effects. A basic requirement for non-invasive imaging tests
in risk-stratification for cardiovascular disease is that they
should provide incremental information over the assessment
of traditional risk factors. Ideally, the same imaging tech-
niques should also be able to gauge the influence of
treatment strategies on disease progression and risk modifi-
cation. Whether an individual imaging strategy will eventually
be incorporated into risk-assessment algorithms will depend
on the strength of the additional information provided rela-
tive to affordability, availability, and ease of use of the
method. Ultrasound imaging is widely available and could
be used for high-throughput screening at low cost, which
compares favourably with other imaging techniques when
being considered as a screening tool in large populations
at risk for atherosclerotic events. This review will briefly
discuss conventional ultrasound imaging methods for the
assessment of atherosclerosis with an emphasis on newer
emerging techniques, and then mainly focus on recent devel-
opments in ultrasound molecular imaging of atherosclerosis.
2. Histomorphometric imaging
Non-invasive ultrasound imaging of morphological changes
related to atherosclerosis has to rely on assessing changes
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in vessels other than the coronary tree. The general assump-
tion is that changes in vessels like the carotid artery that are
easily imaged can serve as surrogate markers for both ather-
osclerotic changes in the coronaries and future risk of cardi-
ovascular events. In its simplest form, B-mode ultrasound
has been used to assess different measures of plaque
burden such as the sum of the maximal thickness of protrud-
ing plaques visualized, or the sum of the total area of all
plaques in the carotid arteries. Plaque burden measured in
elderly men and in patients with known coronary artery
disease has been shown to be an independent predictor of
future cardiovascular mortality and coronary events.6,7
Quite obviously, the clinical utility of a simple assessment
of plaque burden has limitations. First, only changes that
occur relatively late during the disease process can be
imaged, and thus the window of opportunity for preventive
treatments is likely limited. Secondly, B-mode ultrasound
has a limited ability to assess the biological characteristics
of plaques that are known to influence the susceptibility
to cardiovascular events. The first of these limitations has
been addressed by measuring morphological changes in the
vascular intima that occur during the relatively early
stages of the pathogenesis of atherosclerosis. Changes in
intimal thickness are most commonly measured as the
carotid intimal-medial thickness (CIMT), as on B-mode ultra-
sound images only the luminal-intimal interface and the
medial-adventitial interface can reliably be identified.
Several large observational studies have shown that CIMT
is associated with established risk factors for coronary
heart disease and that it is an independent predictor of car-
diovascular events.8–12 However, so far, there have been no
studies published to show that measurements of CIMT
provide incremental prognostic value over the assessment
of traditional risk factors in individual patients. In the afore-
mentioned observational studies, the differences in CIMT
between risk strata are in the order of 200 mm, which is
even below the theoretical, calculated axial resolution of
typical ultrasound equipments used for measurement
of CIMT. Thus, with the current techniques, measurement
of CIMT is most useful when studying large groups of individ-
uals, but it is unlikely that it will be incorporated into
risk-assessment algorithms. Smaller studies have established
that treatment effects of statins, niacin, beta-blockers, and
calcium channel-blocking agents can be assessed by measur-
ing CIMT,13–18 but it has never been shown that these treat-
ment effects translate into reductions in hard clinical
endpoints, and thus CIMT has not been validated as a surro-
gate marker for use in cardiovascular intervention studies.
Intravascular ultrasound (IVUS) of the coronary tree has
provided important new diagnostic information and insight
into the pathogenesis of coronary artery disease. Other
than angiography, greyscale IVUS allows for the assessment
of plaque burden, thus taking into account not only
plaques encroaching on the vascular lumen, but also
plaques with eccentric remodelling. Atheroma burden
measured with IVUS correlates closely with histology.19,20
In addition, characteristics of vulnerable plaques have
been described to include eccentricity of the lesion, and
echolucency in areas of positive remodelling.21 However,
greyscale IVUS is limited for the exact analysis of plaque
composition, with overlap in image characteristics
between calcified and densely fibrotic tissue (strong signal
reflection) on the one hand, and lipid-rich or fibrotic tissue
and intraplaque haemorrhage (low signal reflection) on the
other hand. Accordingly, non-vulnerable plaques in patients
with stable angina have been found to share the aforemen-
tioned characteristics described in unstable lesions.22 The
necessity for more precise evaluation of plaque composition
has resulted in the development of methods that use the raw
backscattered radiofrequency IVUS signal that is not sub-
jected to the same limitations as greyscale data in terms
of dynamic range, compression, and logarithmic transform-
ation. Either the average power of the integrated backscat-
ter23 or spectral analysis of the frequency and power of
backscatter (virtual histology) have been used to this end
(Figure 1).24,25 For these techniques, mathematical algor-
ithms for the classification of plaque components have
been developed based on data aquired postmortem from
human coronary arteries. Initial studies have subsequently
shown good correlation to histology in ex vivo
samples,23,25 and also in vivo when compared with histology
of atherectomy samples.26 However, recent data from
animal studies have questioned the accuracy of this tech-
nique for assessing plaque composition.27
3. Arterial wall biomechanics
Fibrosis, calcification, and smooth muscle cell proliferation
cause changes in the thickness and biomechanical properties
of arterial walls, which translate into increases in Young’s
elastic modulus and other parameters of deformability or
stiffness.28 Changes in the elastic properties will also influ-
ence wave propagation in vessels, and the aortic wave
front propagation velocity measured with either transoeso-
phageal or transthoracic echocardiography has been used
to determine aortic elastance. This parameter correlated
with aortic atheroma burden and was independently predic-
tive of cardiovascular events.29 With IVUS, the elastic prop-
erties of coronary artery walls have been assessed with
elastography. This technique relies on cross-correlation
analysis of radiofrequency signals to derive strain maps of
the artery wall.30,31 Palpography is an identical technique
that is used for interrogating only the luminal surface (to a
depth of about 450 mm), and provides information on the
surface of plaques, where rupture may occur.32,33 Strain
values for potentially vulnerable plaques that contain necro-
tic cores, more inflammatory cells and less smooth muscle
cells than stable lesions have consistently been shown to
have higher strain values,31,32 and strain values have also
been correlated to C-reactive protein levels.32 Recently,
non-invasive elastography has also been used for the assess-
ment of biomechanical properties of the carotid artery in
small pilot studies.34,35
4. Plaque neovascularization
Atherosclerotic plaques rely on the formation of neoves-
sels arising from adventitial vessels or from the lumen
for growth beyond a volume at which nutritients supply
from the arterial lumen or existing adventitial vessels is
not sufficient anymore. It has been noted that the
extent of neovascularization correlates not only with
plaque volume, but also with features of instability like
inflammatory state and morphological plaque rupture.36
Simple colour Doppler techniques have neither the sensi-
tivity nor the spatial resolution to detect plaque
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neovascularization. Contrast-enhanced ultrasound has
been used for the detection of plaque neovessels in the
carotid arteries,37,38 and a semi-quantitative assessment
of plaque neovascularization correlated to neovessels as
visualized by CD31 staining on pathology specimens
(Figure 2).38 Fundamental frequency IVUS imaging is not
sensitive enough for detecting contrast agents in vasa
vasorum in coronary arteries. However, recently harmonic
imaging IVUS instrumentation has been developed and
shown to be capable of detecting ultrasound contrast
agent in the vasa vasorum of the atherosclerotic rabbit
aorta.39
5. Ultrasound molecular imaging
of atherosclerosis
Ultrasound molecular imaging uses microbubbles, other
microparticles like echogenic liposomes, or acoustically
active nanoparticles as tracers. These particles are targeted
to specific molecular structures present on the cell surface
in the tissue of interest. Targeting strategies for micro-
bubbles exploit either the shell characteristics of micropar-
ticles for attachment to activated leukocytes within
inflamed vessels40 or specific targeting by virtue of ligands
that are conjugated to their surface.41 Targeting strategies
for smaller micro- or nanoparticles rely on surface attach-
ment of appropriate ligands. Antibodies, polysaccharides,
and short peptide sequences have been used as targeting
ligands. The concept of ultrasound molecular imaging is
that, after intravenous injection, these microparticles bind
to disease-specific epitopes and can then be imaged non-
invasively in real time. When insonicated, microbubbles
and, to a lesser extent, other accoustically active micropar-
ticles, emit soundwaves that can be detected by ultrasound
systems. While there has been concern on signal damping
caused by attachment to endothelial cells, in vitro studies
have shown that antibody-mediated attachment to endo-
thelial cells leads only to minimal dampening of their
signal, but appears to diminish the rate of gas loss of
these microbubbles.42 In the last few years, several studies
have shown that with these tracers, ultrasound imaging of
molecular targets that are relevant to the development of
atherosclerosis is feasible.
5.1 Molecular targets for ultrasound molecular
imaging of atherosclerosis
Microbubbles do not leave the intravascular space,43 and
thus potential targets must by necessity be present on the
Figure 1 Examples of IVUS B-mode images and corresponding virtual histology (VH) images. On VH images, fibrous areas are marked in green, firbo-fatty in
yellow, dense calcium in white, and necrotic core in red. (A) IVUS grayscale image of a thin-cap fibroatheroma. (B) Colour-coded, reconstructed VH image of
(A) shows a large necrotic core whithout evidence of a fibrous cap. (C) IVUS grayscale image of a fibrocalcific atheroma. (D) Colour-coded VH image of (C)
with the absence of a necrotic core. Note dense calcium at the bottom of the plaque, also visible in (C). Reproduced from Nasu et al.68 with permission
from BMJ Publishing Group Ltd.
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endothelial cell surface. In contrast, acoustically active
microparticles or nanoemulsions can potentially leave the
intravascular space and may allow acoustic targeting of
extravascular structures.44,45
Inflammation plays an important role in the initiation and
progression of cardiovascular disease and has been ident-
ified as a potential diagnostic target. Monocyte and lympo-
hocyte recruitment to the vessel wall is one of the most
important contributors to atherogenesis. These cells serve
as a source for reactive oxygen species, pro-thrombotic
compounds, pro-angiogenic growth factors and cytokines,
vasoactive peptides, and a multitude of bioactive products
that promote smooth muscle cell migration and further
inflammatory cell recruitment. Monocyte and lymphocyte
entry into the vessel wall is tightly regulated and mediated,
in part, by the interaction between endothelial cell
adhesion molecules expressed in inflamed regions and
their counterligands on the leukocyte surface. P-selectin is
a molecule that is responsible for initial capture and rapid
rolling of monocytes and neutrophils on the microvascular
endothelial surface by interacting with its glycosylated and
fucosylated ligand PSGL-1.46 Cytokine-mediated P-selectin
expression can be detected on circulating platelets and is
associated with subclinical atherosclerotic disease in
patients.47 Also, in mouse models of atherosclerosis,
P-selectin-dependent monocyte rolling has been demon-
strated on early atherosclerotic lesions.48 Vascular cell
adhesion molecule 1 (VCAM-1), a cell adhesion molecule
from the immunoglobuline gene superfamily promotes slow
rolling and eventual firm attachment and diapedesis of neu-
trophils, monocytes, and lymphocytes by interacting with
the heterodimeric integrin VLA-4 (a4b1).46 In murine
models of atherosclerotic disease, slow rolling of monocytes
on the surface of atherosclerotic plaques appears to be
largely mediated by VCAM-1.49 Intercellular cell adhesion
molecule 1 (ICAM-1) is a second cell adhesion molecule
from the immunoglobulin gene superfamily that has been
implicated in monocyte recruitment in atherosclerosis.50
With regards to the use of these cell adhesion molecules
as early markers of disease, VCAM-1 has been demonstrated
to be upregulated on the endothelium of Apo E2/2 and LDL
receptor (LDLR)2/2 mice before the development of early
atherosclerotic lesions,51,52 and homozygous VCAM-1 domain
4-deficient mice on a LDLR2/2 background show a slower
progression of atherosclerosis.53 Given the aforementioned
role of VCAM-1 and P-selectin in the early pathogenesis of
atherosclerosis, these markers are thought to be of poten-
tial value in the early assessment of the risk for the develop-
ment of clinical atherosclerotic disease.
Other potential targets for the molecular assessment of
atherosclerosis and/or atherosclerotic plaques include
tissue factor (TF) and several molecular markers of angio-
genesis. TF is not expressed on normal endothelial cells.
However, upon stimulation with cytokines, biogenic amines
such as serotonin or histamine, or by mediators such as oxi-
dized LDL or vascular endothelial growth factor, expression
of TF can be induced on endothelial cells.54 TF has been
related to thrombotic complications after the disruption or
erosion of atherosclerotic plaques.55 In addition, TF is
involved in migratory and proliferative signalling to vascular
smooth muscle cells and could potentially contribute to
plaque progression and destabilization. Thus, there has
been an interest in imaging the expression of TF in plaques
for characterizing the plaque biology and risk for compli-
cations. Likewise, there is interest in imaging molecular
markers of angiogenesis to detect pathological neovascular-
ization associated with plaque progression and instability.
Molecules expressed on the vascular endothelium that
Figure 2 Plaque neovascularization detected by contrast-enhanced ultrasound. (A) and (B) are consecutive ultrasound frames of an atherosclerotic lesion in the
carotid bulb showing microbubbles within the plaque (white arrowheads). (C) Immunohistological staining of the fibrous cap of the lesion imaged in (A) and (B)
showing positive staining for CD31 corresponding to a large first-order neovessel (asterisks) and a smaller second-order neovessel (arrowhead). Reproduced from
Coli et al.38 with permission from Elsevier.
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could potentially be targeted for assessing plaque neovascu-
larization include av integrins, a5 integrins, and VEGF recep-
tors. Ultrasound probes for these targets56–58 have been
developed and employed to detect tumour- or ischaemia-
mediated angiogenesis.
5.2 Targeted microbubble attachment in high shear
flow vessels
The extent of retention of targeted microbubbles on a mol-
ecular marker is determined by ligand density on the tracer
surface, by on- and off-rates of the ligands that are being
used, the wall shear stress within the vasculature of inter-
est, and potentially, by partitioning of the tracer in the
bloodstream. For antibody-targeted microbubbles, the
typical ligand density is .50 000 antibodies per microbubble
or a surface density of several 1000 antibodies per square
micrometre. Ultrasound molecular imaging has been per-
formed in a number of tissues (myocardium, skeletal
muscle, kidney) relying on the selective retention of tar-
geted microbubbles in the microvasculature, where wall
shear stresses are low.41,57,59 Wall shear stress in the com-
monly used murine models of atherosclerosis is much
higher, with peak systolic shear stress reaching up to 80–
90 dynes/cm2, 60,61 in the mouse aorta. Antibody-based
microbubble targeting is the most common and most versa-
tile technique for ultrasound molecular imaging. Given the
low bond formation rate (low on-rate) of antibodies, there
has been concern that this could potentially preclude bond
formation in vessels with rapid transit rates and high shear
stress. Indeed, flow chamber studies performed with vari-
able shear stresses under continuous flow conditions have
shown that the retention fraction of targeted microbubbles
decreases dramatically at shear rates well below the peak
shear rates described in the mouse aorta.62,63 However,
arterial flow is pulsatile, and decreases to near zero during
diastole in the murine aorta. Accordingly, flow chamber
experiments with simulations of pulsatile flow have demon-
strated microbubble attachment with only brief interrup-
tions in high shear rate flow.63 Subsequent resumption of
high shear rate flow does not detach these microbubbles,
indicating excellent bond strength of attached antibody-
targeted microbubbles. Thus, microbubble attachment
does occur in high shear rate conditions provided that the
flow is pulsatile. It is important to realize that wall shear
rates are at least on the order of a magnitude lower in
large arteries in humans, and therefore, with regards to
potential clinical applications, attachment efficiency
should be equivalent or better in humans when compared
with small animal models of disease.
5.3 Feasibility of ultrasound molecular imaging in
atherosclerosis
Microbubbles with a lipid or albumin shell have been shown
to bind to activated monocytes and neutrophils via mechan-
isms that are mediated by complement C3 and/or attach-
ment to Mac-1, and complement-mediated attachment to
endothelial cells is possible for lipid-shelled microbubbles
with a sufficiently negative surface charge.64 Attachment
of perfluorocarbon-exposed sonicated dextrose albumin
(PESDA) microbubbles to dysfunctional endothelium has
also been shown to occur in a pig model of stretch-induced
injury in the carotid arteries during hypertriglceridaemia.65
Subsequent experiments have shown that attachment of
PESDA microbubbles to dysfunctional vascular endothelium
is drastically reduced after complement depletion, and
that extensive attachment also occurs in early atherosclero-
sis in the rat aorta (Figure 3).66
Figure 3 Ultrasound images at low mechanical index and scanning electron microscopy (SEM) of the aortic arch in an atherosclerotic rat (A, B) and a control rat
(C, D) after intravenous injection of PESDA microbubbles. These images illustrate signal from attached PESDA microbubbles in the atherosclerotic rat (A) and
microbubble retention viewed by SEM (B; white arrows). In the control rat, no signal was detected on ultrasound (C), and SEM confirmed the absence of attached
microbubbles. Reproduced from Anderson et al.66 with permission.
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Specific binding of antibody-targeted microbubbles to
endothelial cells has first been demonstrated for ICAM-1-
targeted microbubbles using in vitro experimental
approaches (Figure 4).67 Early in vivo studies involved the
intra-arterial injection of echogenic liposomes targeted to
ICAM-1 in Yucatan miniswines, fed a hypercholesterolaemic
diet after the induction of atherosclerotic plaques by endo-
thelial denudement. Attachment of liposomes to plaques
was then visualized using intravascular and transvascular
ultrasound approaches. Later studies demonstrated selec-
tive attachment and imaging of the cell adhesion molecules
ICAM-1 and VCAM-1 and also of TF after intra-arterial injec-
tions of targeted echogenic liposomes.44 Thus, in these
studies several key mediators of atherosclerosis initiation
and progression could be imaged, albeit with the drawback
that very high intra-arterial doses of liposomes and invasive
imaging methods were used.
Targeting of VCAM-1 in the aorta of atherosclerotic Apo E
lipoprotein-deficient (Apo E2/2) mice has also been
recently accomplished with intravenously injected micro-
bubbles.63 ApoE 2/2 mice develop atherosclerotic
plaques in lesion-prone regions in the aortic arch, the
degree of which can be modified by feeding the animals a
normal chow or high cholesterol diet. Fluorescent
microscopy showed selective attachment of VCAM-1-
targeted microbubbles in these models, and the extent of
attachment correlated to the severity of plaque develop-
ment. Similarly, non-invasive ultrasound imaging of the
aortic arch showed a stepwise increase in VCAM-1-targeted
microbubble signal according to disease phenotype. Thus,
in these studies, disease severity could be non-invasively
imaged by assessing the expression of VCAM-1 (Figure 5).
5.4 Future directions in ultrasound molecular
imaging of atherosclerosis
While the aforementioned studies demonstrate the feasi-
bility of ultrasound molecular imaging in the evaluation of
atherosclerosis, no clinical studies using this technique
have been performed thus far. For the initiation of clinical
trials, several developments need to be made both for the
contrast agents that are being used, as well as in the
imaging technology for tracer detection. Most experimental
studies have used simple biotion-streptavidin-biotin chem-
istry for ligand conjugation to the tracer surface. Streptavi-
din could potentially lead to binding of biotin in the body,
which is needed for fatty acid synthesis and gluconeogen-
esis, and could thus have untoward effects. Alternative con-
jugation strategies that are expected to be safe for human
use include amine or sulfhydryl covalent bonds. Likewise,
there is concern about the use of antibodies in humans
both in terms of safety and costs, and there is a need for
the development of small-molecule, highly specific and
inexpensive ligands which will most certainly include
peptide molecules. For molecular imaging of atherosclero-
sis, attachment of the tracer to a relatively small area like
the endothelial surface of a carotid artery, as opposed to
the microvasculature in a tissue, is required, and only a
limited amount of tracer particles will be available for
detection. Thus, strategies for tracer detection above
Figure 4 Fluorescence microscopy of endothelial cells after incubation with microbubbles bearing either a non-binding control antibody, or an antibody to
ICAM-1. These images show absence of attachment of control microbubbles to non-activated (A) and IL-1b-activated endothelial cells (B). Attachment of micro-
bubbles targeted to ICAM-1 was low in non-activated endothelial cells (C). After IL-1b activation, numerous targeted microbubbles were found attaching to endo-
thelial cells (D). Scale bar ¼ 10 mm. Of note, the microbubbles have lost their gas and spherical shape owing to preparation for microscopy. Reproduced from
Villanueva et al.67 with permission.
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background noise in arteries with strong specular reflection
need to be optimized. In addition, algorithms for online
detection of attached microbubbles only are desirable. It
should also be emphasized that once the aforementioned
technological advances have been accomplished, initial
clinical trials will most certainly include imaging of readily
accessible vessels like the carotid arteries, and inflamma-
tory or other molecular changes that are detected will
serve as surrogate markers for cardiovascular risk.
However, there is a keen interest in molecular imaging of
the coronary arteries, especially for the detection of vulner-
able plaques, that will make further refinement of ultra-
sound imaging equipment and tracer design necessary.
6. Conclusions
Enormous progress has been made in the last years in unco-
vering the molecular mechanisms that lead to initiation and
progression of atherosclerosis. Undoubtedly, this research
will eventually translate into new therapeutic approaches.
This creates a need for the non-invasive assessment of
atherosclerosis on a subcellular level for earlier recognition
of disease or for better evaluation of risk and disease pro-
gression in established disease, as well as for the assessment
of the effect of existing and new, costly therapies. Athero-
sclerosis and risk factors for the development of athero-
sclerosis are highly prevalent, and therefore such
non-invasive imaging techniques need to offer high through-
put, widely available and inexpensive screening capabilities.
The ultrasound imaging techniques described in this review
are well positioned for eventually satisfying these
requirements.
Funding
B.A.K. is supported by grant 32323B_123819/1 from the
Swiss National Science Foundation and by a grant from the
Swiss Heart Foundation.
Conflict of interest: none declared.
References
1. Ford ES, Capewell S. Coronary heart disease mortality among young
adults in the U.S. from 1980 through 2002: concealed leveling of mor-
tality rates. J Am Coll Cardiol 2007;50:2128–2132.
2. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB,
Flegal K et al. Heart Disease and Stroke Statistics–2009 Update. A
Report From the American Heart Association Statistics Committee and
Stroke Statistics Subcommittee. Circulation 2009;119:480–486.
3. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in
obesity among US adults, 1999–2000. JAMA 2002;288:1723–1727.
4. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic
syndrome among US Adults. Diabetes Care 2004;27:2444–2449.
5. Jacobson TA, Griffiths GG, Varas C, Gause D, Sung JC, Ballantyne CM.
Impact of evidence-based ‘clinical judgment’ on the number of American
adults requiring lipid-lowering therapy based on updated NHANES III data.
National Health and Nutrition Examination Survey. Arch Intern Med 2000;
160:1361–1369.
6. Stork S, van den Beld AW, von Schacky C, Angermann CE, Lamberts SW,
Grobbee DE et al. Carotid artery plaque burden, stiffness, and mortality
risk in elderly men: a prospective, population-based cohort study. Circu-
lation 2004;110:344–348.
7. Chan SY, Mancini GB, Kuramoto L, Schulzer M, Frohlich J, Ignaszewski A.
The prognostic importance of endothelial dysfunction and carotid ather-
oma burden in patients with coronary artery disease. J Am Coll Cardiol
2003;42:1037–1043.
8. Chambless LE, Folsom AR, Davis V, Sharrett R, Heiss G, Sorlie P et al. Risk
factors for progression of common carotid atherosclerosis: the Athero-
sclerosis Risk in Communities Study, 1987–1998. Am J Epidemiol 2002;
155:38–47.
Figure 5 Examples of contrast-enhanced ultrasound targeted imaging of VCAM-1 in Apo E2/2 mice on high cholesterol diet. These images show low signal from
control microbubbles (A) and high signal from VCAM-1-targeted microbubbles (B). Fluorescent microscopy revealed extensive attachment of VCAM-1-targeted
microbubbles to the aortic endothelium in Apo E2/2 mice on high cholesterol diet (C). Immunohistological staining for VCAM-1 in these mice revealed extensive
plaque formation (D) with expression of VCAM-1 both on the endothelial surface and on macrophages within the plaque (E).
Ultrasound molecular imaging of atherosclerosis 623
9. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR
et al. Association of coronary heart disease incidence with carotid arter-
ial wall thickness and major risk factors: the Atherosclerosis Risk in
Communities [ARIC] Study, 1987–1993. Am J Epidemiol 1997;146:
483–494.
10. Chambless LE, Folsom AR, Clegg LX, Sharrett AR, Shahar E, Nieto FJ et al.
Carotid wall thickness is predictive of incident clinical stroke: the Ather-
osclerosis Risk in Communities [ARIC] study. Am J Epidemiol 2000;151:
478–487.
11. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK.
Carotid-artery intima and media thickness as a risk factor for myocardial
infarction and stroke in older adults. Cardiovascular Health Study Colla-
borative Research Group. N Engl J Med 1999;340:14–22.
12. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid
intima-media thickness and risk of stroke and myocardial infarction: the
Rotterdam Study. Circulation 1997;96:1432–1437.
13. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN.
ARBITER: Arterial Biology for the Investigation of the Treatment Effects
of Reducing Cholesterol: a randomized trial comparing the effects of
atorvastatin and pravastatin on carotid intima medial thickness. Circula-
tion 2002;106:2055–2060.
14. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for
the Investigation of the Treatment Effects of Reducing Cholesterol
[ARBITER] 2: a double-blind, placebo-controlled study of extended-
release niacin on atherosclerosis progression in secondary prevention
patients treated with statins. Circulation 2004;110:3512–3517.
15. Hedblad B, Wikstrand J, Janzon L, Wedel H, Berglund G. Low-dose meto-
prolol CR/XL and fluvastatin slow progression of carotid intima-media
thickness: main results from the Beta-Blocker Cholesterol-Lowering
Asymptomatic Plaque Study (BCAPS). Circulation 2001;103:
1721–1726.
16. Wiklund O, Hulthe J, Wikstrand J, Schmidt C, Olofsson SO, Bondjers G.
Effect of controlled release/extended release metoprolol on carotid
intima-media thickness in patients with hypercholesterolemia: a 3-year
randomized study. Stroke 2002;33:572–577.
17. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME
et al. Effect of amlodipine on the progression of atherosclerosis and
the occurrence of clinical events. PREVENT Investigators. Circulation
2000;102:1503–1510.
18. Smilde TJ, van WS, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF.
Effect of aggressive versus conventional lipid lowering on atherosclerosis
progression in familial hypercholesterolaemia (ASAP): a prospective, ran-
domised, double-blind trial. Lancet 2001;357:577–581.
19. Potkin BN, Bartorelli AL, Gessert JM, Neville RF, Almagor Y, Roberts WC
et al. Coronary artery imaging with intravascular high-frequency ultra-
sound. Circulation 1990;81:1575–1585.
20. Nishimura RA, Edwards WD, Warnes CA, Reeder GS, Holmes DR, Tajik AJ
et al. Intravascular ultrasound imaging: in vitro validation and pathologic
correlation. J Am Coll Cardiol 1990;16:145–154.
21. Yamagishi M, Terashima M, Awano K, Kijima M, Nakatani S, Daikoku S
et al. Morphology of vulnerable coronary plaque: insights from follow-up
of patients examined by intravascular ultrasound before an acute coron-
ary syndrome. J Am Coll Cardiol 2000;35:106–111.
22. Schoenhagen P, Stone GW, Nissen SE, Grines CL, Griffin J, Clemson BS
et al. Coronary plaque morphology and frequency of ulceration distant
from culprit lesions in patients with unstable and stable presentation.
Arterioscler Thromb Vasc Biol 2003;23:1895–1900.
23. Kawasaki M, Takatsu H, Noda T, Sano K, Ito Y, Hayakawa K et al. In vivo
quantitative tissue characterization of human coronary arterial plaques
by use of integrated backscatter intravascular ultrasound and comparison
with angioscopic findings. Circulation 2002;105:2487–2492.
24. Nair A, Kuban BD, Obuchowski N, Vince DG. Assessing spectral algorithms
to predict atherosclerotic plaque composition with normalized and raw
intravascular ultrasound data. Ultrasound Med Biol 2001;27:1319–1331.
25. Nair A, Kuban BD, Tuzcu EM, Schoenhagen P, Nissen SE, Vince DG. Coron-
ary plaque classification with intravascular ultrasound radiofrequency
data analysis. Circulation 2002;106:2200–2206.
26. Nasu K, Tsuchikane E, Katoh O, Vince DG, Virmani R, Surmely JF et al.
Accuracy of in vivo coronary plaque morphology assessment: a validation
study of in vivo virtual histology compared with in vitro histopathology.
J Am Coll Cardiol 2006;47:2405–2412.
27. Granada JF, Wallace-Bradley D, Win HK, Alviar CL, Builes A, Lev EI et al.
In vivo plaque characterization using intravascular ultrasound-virtual his-
tology in a porcine model of complex coronary lesions. Arterioscler
Thromb Vasc Biol 2007;27:387–393.
28. Lee RT, Grodzinsky AJ, Frank EH, Kamm RD, Schoen FJ. Structure-
dependent dynamic mechanical behavior of fibrous caps from human
atherosclerotic plaques. Circulation 1991;83:1764–1770.
29. Hunziker PR, Imsand C, Keller D, Hess N, Barbosa V, Nietlisbach F et al.
Bedside quantification of atherosclerosis severity for cardiovascular risk
stratification: a prospective cohort study. J Am Coll Cardiol 2002;39:
702–709.
30. de Korte CL, van der Steen AF, Cespedes EI, Pasterkamp G. Intravascular
ultrasound elastography in human arteries: initial experience in vitro.
Ultrasound Med Biol 1998;24:401–408.
31. Schaar JA, de Korte CL, Mastik F, Strijder C, Pasterkamp G, Boersma E
et al. Characterizing vulnerable plaque features with intravascular elas-
tography. Circulation 2003;108:2636–2641.
32. Schaar JA, Regar E, Mastik F, McFadden EP, Saia F, Disco C et al. Incidence
of high-strain patterns in human coronary arteries: assessment with
three-dimensional intravascular palpography and correlation with clini-
cal presentation. Circulation 2004;109:2716–2719.
33. Schaar JA, van der Steen AF, Mastik F, Baldewsing RA, Serruys PW. Intra-
vascular palpography for vulnerable plaque assessment. J Am Coll
Cardiol 2006;47:C86–C91.
34. Maurice RL, Soulez G, Giroux MF, Cloutier G. Noninvasive vascular elasto-
graphy for carotid artery characterization on subjects without previous
history of atherosclerosis. Med Phys 2008;35:3436–3443.
35. Schmitt C, Soulez G, Maurice RL, Giroux MF, Cloutier G. Noninvasive vas-
cular elastography: toward a complementary characterization tool of
atherosclerosis in carotid arteries. Ultrasound Med Biol 2007;33:
1841–1858.
36. Moreno PR, Purushothaman KR, Fuster V, Echeverri D, Truszczynska H,
Sharma SK et al. Plaque neovascularization is increased in ruptured
atherosclerotic lesions of human aorta: implications for plaque vulner-
ability. Circulation 2004;110:2032–2038.
37. Vicenzini E, Giannoni MF, Puccinelli F, Ricciardi MC, Altieri M, DiPiero V
et al. Detection of carotid adventitial vasa vasorum and plaque vascular-
ization with ultrasound cadence contrast pulse sequencing technique and
echo-contrast agent. Stroke 2007;38:2841–2843.
38. Coli S, Magnoni M, Sangiorgi G, Morrocco-Trischitta MM, Melisurgo G,
Mauriello A et al. Contrast-enhanced ultrasound imaging of intraplaque
neovascularization in carotid arteries: correlation with histology and
plaque echogenicity. J Am Coll Cardiol 2008;52:223–230.
39. Goertz DE, Frijlink ME, Tempel D, van Damme LC, Krams R, Schaar JA
et al. Contrast harmonic intravascular ultrasound: a feasibility study
for vasa vasorum imaging. Invest Radiol 2006;41:631–638.
40. Christiansen JP, Leong-Poi H, Klibanov AL, Kaul S, Lindner JR. Noninvasive
imaging of myocardial reperfusion injury using leukocyte-targeted con-
trast echocardiography. Circulation 2002;105:1764–1767.
41. Lindner JR, Song J, Christiansen J, Klibanov AL, Xu F, Ley K. Ultrasound
assessment of inflammation and renal tissue injury with microbubbles
targeted to P-selectin. Circulation 2001;104:2107–2112.
42. Lankford M, Behm CZ, Yeh J, Klibanov AL, Robinson P, Lindner JR. Effect
of microbubble ligation to cells on ultrasound signal enhancement: impli-
cations for targeted imaging. Invest Radiol 2006;41:721–728.
43. Jayaweera AR, Edwards N, Glasheen WP, Villanueva FS, Abbott RD,
Kaul S. In vivo myocardial kinetics of air-filled albumin microbubbles
during myocardial contrast echocardiography. Comparison with radio-
labeled red blood cells. Circ Res 1994;74:1157–1165.
44. Hamilton AJ, Huang SL, Warnick D, Rabbat M, Kane B, Nagaraj A et al.
Intravascular ultrasound molecular imaging of atheroma components in
vivo. J Am Coll Cardiol 2004;43:453–460.
45. Lanza GM, Abendschein DR, Hall CS, Marsh JN, Scott MJ, Scherrer DE
et al. Molecular imaging of stretch-induced tissue factor expression in
carotid arteries with intravascular ultrasound. Invest Radiol 2000;35:
227–234.
46. Yang J, Hirata T, Croce K, Merrill-Skoloff G, Tchernychev B, Williams E
et al. Targeted gene disruption demonstrates that P-selectin glycoprotein
ligand 1 [PSGL-1] is required for P-selectin-mediated but not
E-selectin-mediated neutrophil rolling and migration. J Exp Med 1999;
190:1769–1782.
47. Shimizu M, Kohara S, Yamamoto M, Ando Y, Haida M, Shinohara Y. Signifi-
cant relationship between platelet activation and intra-media thickness
of the carotid artery in patients with ischemic cerebrovascular disease.
Thromb Res 2006;117:647–652.
48. Ramos CL, Huo Y, Jung U, Ghosh S, Manka DR, Sarembock IJ et al. Direct
demonstration of P-Selectin- and VCAM-1-dependent mononuclear cell
rolling in early atherosclerotic lesions of apolipoprotein e-deficient
mice. Circ Res 1999;84:1237–1244.
B.A. Kaufmann624
49. Dansky HM, Barlow CB, Lominska C, Sikes JL, Kao C, Weinsaft J et al.
Adhesion of monocytes to arterial endothelium and initiation of athero-
sclerosis are critically dependent on vascular cell adhesion molecule-1
gene dosage. Arterioscler Thromb Vasc Biol 2001;21:1662–1667.
50. Walpola PL, Gotlieb AI, Cybulsky MI, Langille BL. Expression of ICAM-1 and
VCAM-1 and monocyte adherence in arteries exposed to altered shear
stress. Arterioscler Thromb Vasc Biol 1995;15:2–10.
51. Iiyama K, Hajra L, Iiyama M, Li H, DiChiara M, Medoff BD et al. Patterns of
vascular cell adhesion molecule-1 and intercellular adhesion molecule-1
expression in rabbit and mouse atherosclerotic lesions and at sites predis-
posed to lesion formation. Circ Res 1999;85:199–207.
52. Nakashima Y, Raines EW, Plump AS, Breslow JL, Ross R. Upregulation of
VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium
in the ApoE-deficient mouse. Arterioscler Thromb Vasc Biol 1998;18:
842–851.
53. Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M et al. A major role
for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001;
107:1255–1262.
54. Steffel J, Luscher TF, Tanner FC. Tissue factor in cardiovascular diseases:
molecular mechanisms and clinical implications. Circulation 2006;113:
722–731.
55. Marmur JD, Thiruvikraman SV, Fyfe BS, Guha A, Sharma SK, Ambrose JA
et al. Identification of active tissue factor in human coronary atheroma.
Circulation 1996;94:1226–1232.
56. Leong-Poi H, Christiansen J, Heppner P, Lewis CW, Klibanov AL, Kaul S
et al. Assessment of endogenous and therapeutic arteriogenesis by con-
trast ultrasound molecular imaging of integrin expression. Circulation
2005;111:3248–3254.
57. Behm CZ, Kaufmann BA, Carr C, Lankford M, Sanders JM, Rose CE et al.
Molecular imaging of endothelial vascular cell adhesion molecule-1
expression and inflammatory cell recruitment during vasculogenesis
and ischemia-mediated arteriogenesis. Circulation 2008;117:
2902–2911.
58. Willmann JK, Paulmurugan R, Chen K, Gheysens O, Rodriguez-Porcel M,
Lutz AM et al. US imaging of tumor angiogenesis with microbubbles
targeted to vascular endothelial growth factor receptor type 2 in mice.
Radiology 2008;246:508–518.
59. Kaufmann BA, Lewis C, Xie A, Mirza-Mohd A, Lindner JR. Detection of
recent myocardial ischaemia by molecular imaging of P-selectin with tar-
geted contrast echocardiography. Eur Heart J 2007;28:2011–2017.
60. Eriksson EE, Werr J, Guo Y, Thoren P, Lindbom L. Direct observations in
vivo on the role of endothelial selectins and alpha[4] integrin in
cytokine-induced leukocyte-endothelium interactions in the mouse
aorta. Circ Res 2000;86:526–533.
61. Greve JM, Les AS, Tang BT, Draney Blomme MT, Wilson NM, Dalman RL
et al. Allometric scaling of wall shear stress from mice to humans: quanti-
fication using cine phase-contrast MRI and computational fluid dynamics.
Am J Physiol Heart Circ Physiol 2006;291:H1700–H1708.
62. Takalkar AM, Klibanov AL, Rychak JJ, Lindner JR, Ley K. Binding and
detachment dynamics of microbubbles targeted to P-selectin under con-
trolled shear flow. J Control Release 2004;96:473–482.
63. Kaufmann BA, Sanders JM, Davis C, Xie A, Aldred P, Sarembock IJ et al.
Molecular imaging of inflammation in atherosclerosis with targeted ultra-
sound detection of vascular cell adhesion molecule-1. Circulation 2007;
116:276–284.
64. Lindner JR, Coggins MP, Kaul S, Klibanov AL, Brandenburger GH, Ley K.
Microbubble persistence in the microcirculation during ischemia/
reperfusion and inflammation is caused by integrin- and complement-
mediated adherence to activated leukocytes. Circulation 2000;101:
668–675.
65. Tsutsui JM, Xie F, Cano M, Chomas J, Philipps P, Radio SJ et al. Detection
of retained microbubbles in carotid arteries with real-time low mechan-
ical index imaging in the setting of endothelial dysfunction. J Am Coll
Cardiol 2004;44:1036–1046.
66. Anderson DR, Tsutsui JM, Xie F, Radio SJ, Porter TR. The role of
complement in the adherence of microbubbles to dysfunctional arterial
endothelium and atherosclerotic plaque. Cardiovasc Res 2007;73:
597–606.
67. Villanueva FS, Jankowski RJ, Klibanov S, Pina ML, Alber SM, Watkins SC
et al. Microbubbles targeted to intercellular adhesion molecule-1 bind
to activated coronary artery endothelial cells. Circulation 1998;98:1–5.
68. Nasu K, Tsuchikane E, Katoh O, Fujita H, Surmely JF, Ehara M et al. Plaque
characterisation by virtual histology intravascular ultrasound analysis in
patients with type 2 diabetes. Heart 2008;94:429–433.
Ultrasound molecular imaging of atherosclerosis 625
